RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
about
Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells.A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.Alterations of the WNT7A gene in clear cell renal cell carcinomasHypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma.Identification and comparison of aberrant key regulatory networks in breast, colon, liver, lung, and stomach cancers through methylome database analysisClinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients.Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.Epigenetics as a therapeutic target in breast cancer.CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer.RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients.Quantitation of CDH1 promoter methylation in formalin-fixed paraffin-embedded tissues of breast cancer patients using differential high resolution melting analysis.Methylation pattern of CDH1 promoter and its association with CDH1 gene expression in cytological cervical specimens.PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapyBRCA2 carriers with male breast cancer show elevated tumour methylation.Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA.Methylation biomarkers for pleomorphic lobular breast cancer - a short report.
P2860
Q33671991-642518C3-8F83-4CC0-ADF5-09E176005E76Q34194620-9AA7C7A3-1901-4FE9-B1E7-9931ECF1A73EQ34442670-1DFDE8CA-74AF-41AD-A0C4-1025CE9006C5Q35016547-85DC1AC9-1EE5-464D-94D7-BBE431115A44Q35171241-55F952D9-C922-49DF-9A37-B70B5B515753Q36197208-592706A8-D160-4340-A8BA-4094C2F35A69Q36414347-26595C22-F37B-4527-8BEA-D1D1CCDCEFB9Q36449057-06EA53E9-0918-46DD-9252-9D78A9A82793Q36741554-FC455C67-AB18-4653-9669-608F05C01C71Q36865048-21EBB0E9-DD2D-4EEB-A204-A4002F1694BDQ37006733-A05CACEE-FDB1-44F4-B047-1D17F4957000Q37289411-D3BD31B9-8203-44FE-81D5-C609F35B3DEEQ37367387-29E05AD1-812B-4FE7-953F-5EB0BD9E7525Q41274606-BC7D5C98-276B-4CB6-8387-E2069132B30FQ50055284-6D581494-0B16-45D3-9E0D-40EA28EDFB6EQ50929938-5063ED49-7529-414C-9979-339368305141Q53118366-3A2D1135-7D2C-4500-A9A1-4977B2BDC403Q54317130-DC1BAD46-CF86-4AA1-A15D-C4114014B96E
P2860
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
@en
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
@nl
type
label
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
@en
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
@nl
prefLabel
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
@en
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
@nl
P2093
P356
P1433
P1476
RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer
@en
P2093
Ivana Fridrichova
Iveta Stankovicova
Iveta Zmetakova
Karol Kajo
Katarina Sebova
Miroslav Tomka
Tomas Krivulcik
Viera Kajabova
Vladimir Bella
Zora Lasabova
P356
10.3233/CBM-2012-0230
P577
2011-01-01T00:00:00Z